Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus vaccine H5N1 - Seqirus

Drug Profile

Influenza A virus vaccine H5N1 - Seqirus

Alternative Names: Aflunov; aH5N1c; FCC H5N1; Flu Cell Culture H5N1; Influenza A virus strain H5N1 vaccine - Seqirus; MF59™-adjuvanted-H5N1 subunit vaccine; Pre-pandemic H5N1 influenza vaccine - Seqirus; Pre-pandemic influenza vaccine - Seqirus

Latest Information Update: 01 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis; Novartis Vaccines
  • Developer Seqirus
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 05 Oct 2017 Seqirus plans a phase II trial for Influenza-A virus H5N1 subtype in Estonia (EudraCT2016-001898-32)
  • 04 Oct 2017 Seqirus completes a phase III trial in Influenza-A virus H5N1 subtype (In adults, In the elderly, Prevention) in USA (IM) (NCT02839330)
  • 01 Jul 2016 Phase-III clinical trials in Influenza-A virus H5N1 subtype (In adults, In the elderly, Prevention) in USA (IM) (NCT02839330)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top